111 related articles for article (PubMed ID: 8701030)
1. Inhibition of pentagastrin-induced pressor response in conscious rats by the CCK-B receptor antagonist CI-988 and chlordiazepoxide.
Webb JK; Rupniak NM; Boyce S
Regul Pept; 1996 Jan; 61(1):71-6. PubMed ID: 8701030
[TBL] [Abstract][Full Text] [Related]
2. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety.
Singh L; Lewis AS; Field MJ; Hughes J; Woodruff GN
Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1130-3. PubMed ID: 1996314
[TBL] [Abstract][Full Text] [Related]
3. The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist.
Singh L; Field MJ; Hughes J; Menzies R; Oles RJ; Vass CA; Woodruff GN
Br J Pharmacol; 1991 Sep; 104(1):239-45. PubMed ID: 1686205
[TBL] [Abstract][Full Text] [Related]
4. Several roles of CCKA and CCKB receptor subtypes in CCK-8-induced and LiCl-induced taste aversion conditioning.
Mosher JT; Johnson MF; Birkemo LS; Ervin GN
Peptides; 1996; 17(3):483-8. PubMed ID: 8735976
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.
Nishida A; Miyata K; Tsutsumi R; Yuki H; Akuzawa S; Kobayashi A; Kamato T; Ito H; Yamano M; Katuyama Y
J Pharmacol Exp Ther; 1994 May; 269(2):725-31. PubMed ID: 7910212
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the receptors and mechanisms involved in the cardiovascular actions of sCCK-8 in the pithed rat.
Gaw AJ; Hills DM; Spraggs CF
Br J Pharmacol; 1995 Jun; 115(4):660-4. PubMed ID: 7582487
[TBL] [Abstract][Full Text] [Related]
7. Role of N- and C-terminal substituents on the CCK-B agonist-antagonist pharmacological profile of Boc-Trp-Phg-Asp-Nal-NH2 derivatives.
Weng JH; Blommaert AG; Moizo L; Bado A; Ducos B; Böhme A; Garbay C; Roques BP
Bioorg Med Chem; 1996 Apr; 4(4):563-73. PubMed ID: 8735845
[TBL] [Abstract][Full Text] [Related]
8. Spinal effect of the cholecystokinin-B receptor antagonist CI-988 on hyperalgesia, allodynia and morphine-induced analgesia in diabetic and mononeuropathic rats.
Coudoré-Civiale MA; Courteix C; Fialip J; Boucher M; Eschalier A
Pain; 2000 Oct; 88(1):15-22. PubMed ID: 11098095
[TBL] [Abstract][Full Text] [Related]
9. Effects of the CCK(A) receptor antagonists SR 27897B and PD140548 on baroreflex function in conscious rats.
Bunting MW; Beart PM; Widdop RE
Eur J Pharmacol; 1997 Oct; 337(1):35-9. PubMed ID: 9389378
[TBL] [Abstract][Full Text] [Related]
10. Characterization of CCK receptors in a novel smooth muscle preparation from the guinea-pig stomach by use of the selective antagonists CI-988, L-365,260 and devazepide.
Boyle SJ; Tang KW; Woodruff GN; McKnight AT
Br J Pharmacol; 1993 Aug; 109(4):913-7. PubMed ID: 8401944
[TBL] [Abstract][Full Text] [Related]
11. Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo.
Patel S; Smith AJ; Chapman KL; Fletcher AE; Kemp JA; Marshall GR; Hargreaves RJ; Ryecroft W; Iversen LL; Iversen SD
Mol Pharmacol; 1994 Nov; 46(5):943-8. PubMed ID: 7969084
[TBL] [Abstract][Full Text] [Related]
12. The cholecystokinin-induced increase in intracellular calcium in AR42J cells is mediated by CCKB receptors linked to internal calcium stores.
Pinnock RD; Suman-Chauhan N; Daum P; Hill DR; Woodruff GN
Neuropeptides; 1994 Sep; 27(3):175-83. PubMed ID: 7816188
[TBL] [Abstract][Full Text] [Related]
13. CI 988, an antagonist of the cholecystokinin-B receptor, potentiates endogenous opioid-mediated antinociception at spinal level.
Xu XJ; Elfvin A; Hao JX; Fournié-Zaluski MC; Roques BP; Wiesenfeld-Hallin Z
Neuropeptides; 1997 Jun; 31(3):287-91. PubMed ID: 9243527
[TBL] [Abstract][Full Text] [Related]
14. Activation of amygdala cholecystokininB receptors potentiates the acoustic startle response in the rat.
Frankland PW; Josselyn SA; Bradwejn J; Vaccarino FJ; Yeomans JS
J Neurosci; 1997 Mar; 17(5):1838-47. PubMed ID: 9030642
[TBL] [Abstract][Full Text] [Related]
15. Cholecystokinin B receptors in the periaqueductal gray potentiate defensive rage behavior elicited from the medial hypothalamus of the cat.
Luo B; Cheu JW; Siegel A
Brain Res; 1998 Jun; 796(1-2):27-37. PubMed ID: 9689451
[TBL] [Abstract][Full Text] [Related]
16. Anxiogenic effect of cholecystokinin in the dorsal periaqueductal gray.
Netto CF; Guimarães FS
Neuropsychopharmacology; 2004 Jan; 29(1):101-7. PubMed ID: 14583742
[TBL] [Abstract][Full Text] [Related]
17. Cholecystokinin B antagonists. Synthesis and quantitative structure-activity relationships of a series of C-terminal analogues of CI-988.
Augelli-Szafran CE; Horwell DC; Kneen C; Ortwine DF; Pritchard MC; Purchase TS; Roth BD; Trivedi BK; Hill D; Suman-Chauhan N; Webdale L
Bioorg Med Chem; 1996 Oct; 4(10):1733-45. PubMed ID: 8931944
[TBL] [Abstract][Full Text] [Related]
18. CCK-B receptors in the limbic system modulate the antidepressant-like effects induced by endogenous enkephalins.
Smadja C; Ruiz F; Coric P; Fournié-Zaluski MC; Roques BP; Maldonado R
Psychopharmacology (Berl); 1997 Aug; 132(3):227-36. PubMed ID: 9292622
[TBL] [Abstract][Full Text] [Related]
19. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.
Semple G; Ryder H; Rooker DP; Batt AR; Kendrick DA; Szelke M; Ohta M; Satoh M; Nishida A; Akuzawa S; Miyata K
J Med Chem; 1997 Jan; 40(3):331-41. PubMed ID: 9022799
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of the cholecystokinin-B receptor antagonist, PD 134308, and the cholecystokinin-A receptor antagonist, L-364,718, on dopamine neuronal activity in the substantia nigra and ventral tegmental area.
Meltzer LT; Christoffersen CL; Serpa KA; Razmpour A
Synapse; 1993 Feb; 13(2):117-22. PubMed ID: 8446920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
